Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease
Expert Opinion on Investigational Drugs · 03.04.2023 · 32 (4) · 291-299
DOI: 10.1080/13543784.2023.2196010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Investigational Drugs, online erschienen am 03.04.2023. Verfasst von Adel Dihoum und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tenovus.
Abstract (Originalsprache)
INTRODUCTION: For a long time, metformin has been the first-line treatment for glycemic control in type 2 diabetes; however, the results of recent cardiovascular outcome trials of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have caused many to question metformin's position in the guidelines. Although there are several plausible mechanisms by which metformin might have beneficial cardiovascular effects, for example, its anti-inflammatory effects and metabolic properties, and numerous observational data suggesting improved cardiovascular outcomes with metformin use, the main randomized clinical trial data for metformin was published over 20 years ago. Nevertheless, the overwhelming majority of participants in contemporary type 2 diabetes trials were prescribed metformin. AREAS COVERED: In this review, we will summarize the potential mechanisms of cardiovascular benefit with metformin, before discussing clinical data in individuals with or without diabetes. EXPERT OPINION: Metformin may have some cardiovascular benefit in patients with and without diabetes, however the majority of clinical trials were small and are before the use SGLT2 inhibitors and GLP1-RAs. Larger contemporary randomized trials, with metformin evaluating its cardiovascular benefit are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
- Division of Cellular Medicine, University of Dundee, Dundee, UK.
- Division of Population Health and Genomics, University of Dundee, Dundee, UK.
ORCID-Profile: Ify R Mordi
Förderung
- Tenovus
Zitieren
APA
Dihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023). Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. Expert Opinion on Investigational Drugs, 32(4), 291-299. https://doi.org/10.1080/13543784.2023.2196010
Vancouver
Dihoum A, Rena G, Pearson ER, Lang CC, Mordi IR. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. Expert Opinion on Investigational Drugs. 2023;32(4):291-299. doi:10.1080/13543784.2023.2196010
BibTeX
@article{Dihoum2023,
author = {Dihoum, Adel and Rena, Graham and Pearson, Ewan R and Lang, Chim C and Mordi, Ify R},
title = {Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease},
journal = {Expert Opinion on Investigational Drugs},
year = {2023},
volume = {32},
number = {4},
pages = {291--299},
doi = {10.1080/13543784.2023.2196010}
}
EUVIMED